Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Quoin Pharmaceuticals Ltd DRC (QNRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: QNRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $150
1 Year Target Price $150
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.44% | Avg. Invested days 19 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.22M USD | Price to earnings Ratio - | 1Y Target Price 150 |
Price to earnings Ratio - | 1Y Target Price 150 | ||
Volume (30-day avg) 2 | Beta 1.78 | 52 Weeks Range 5.01 - 37.80 | Updated Date 07/8/2025 |
52 Weeks Range 5.01 - 37.80 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -34.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.4% | Return on Equity (TTM) -138.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -6329801 | Price to Sales(TTM) - |
Enterprise Value -6329801 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.42 | Shares Outstanding 588167 | Shares Floating 18047816 |
Shares Outstanding 588167 | Shares Floating 18047816 | ||
Percent Insiders 7.08 | Percent Institutions 7.2 |
Upturn AI SWOT
Quoin Pharmaceuticals Ltd DRC
Company Overview
History and Background
Quoin Pharmaceuticals, founded in 2017, is a specialty pharmaceutical company focused on rare and orphan diseases. It licenses and develops products to address unmet medical needs, particularly in dermatology.
Core Business Areas
- Dermatology: Focuses on developing and commercializing products for rare skin diseases.
Leadership and Structure
Details on the leadership team and organizational structure were not available in my knowledge cut-off
Top Products and Market Share
Key Offerings
- QRX003: Lead product candidate is being developed for Netherton Syndrome. Currently in clinical development. No market share or revenue information available as it's not yet approved. Competitors depend on which symptoms QRX003 effectively alleviates, but could include companies that make emollients.
Market Dynamics
Industry Overview
The rare disease market is growing, driven by increased awareness, regulatory incentives, and advancements in diagnostics. Dermatology is a lucrative segment within pharmaceuticals.
Positioning
Quoin is positioned as a developer of niche treatments for rare dermatological conditions. Its competitive advantage depends on the successful development and commercialization of its pipeline.
Total Addressable Market (TAM)
The TAM depends on the specific rare diseases Quoin targets. Netherton Syndrome affects a relatively small population, but the pricing of orphan drugs can result in significant revenue potential if a product is approved.
Upturn SWOT Analysis
Strengths
- Focus on rare diseases
- Potential for orphan drug designation and market exclusivity
- Experienced management team
Weaknesses
- Reliance on a limited number of pipeline products
- High risk associated with drug development
- Need for significant capital to fund research and development
Opportunities
- Expansion of pipeline through licensing or acquisitions
- Strategic partnerships with larger pharmaceutical companies
- Increased awareness and diagnosis of rare diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing treatments for rare diseases
- Manufacturing or supply chain issues
Competitors and Market Share
Key Competitors
- This information is not available without comprehensive market research. Companies competing in similar therapeutic areas may exist.
Competitive Landscape
Quoin's advantage depends on the uniqueness and efficacy of its products. They will have to navigate complex regulatory and competitive factors.
Growth Trajectory and Initiatives
Historical Growth: The company's historical growth is tied to the progression of its pipeline.
Future Projections: Future growth depends on successful clinical trials and regulatory approvals.
Recent Initiatives: Recent initiatives likely include clinical trial activities and potential partnership discussions.
Summary
Quoin Pharmaceuticals is a development-stage pharmaceutical company focused on rare diseases, primarily in dermatology. Its success hinges on the successful development and commercialization of its lead product candidates. Clinical trial outcomes, regulatory approvals, and securing necessary financing are critical factors for its future growth. Due to its early stage, the company is speculative.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (where available)
- Publicly available news and information
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Quoin Pharmaceuticals Ltd DRC
Exchange NASDAQ | Headquaters Ashburn, VA, United States | ||
IPO Launch date 2016-07-29 | Co-Founder, CEO & Chairman Dr. Michael Myers Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3 | Website https://quoinpharma.com |
Full time employees 3 | Website https://quoinpharma.com | ||
Quoin Pharmaceuticals, Ltd., a late stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). It also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat Netherton Syndrome; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.